Trastuzumab for HER2-Positive Breast Cancer
In these randomized studies of women with nonmetastatic disease, those who received adjuvant chemotherapy plus trastuzumab had a better chance of 2-year disease-free survival than did those who received adjuvant chemotherapy alone.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)